Publications by authors named "K Ioannidis"
Self-assembled cartilaginous microtissues provide a promising means of repairing challenging skeletal defects and connective tissues. However, despite their considerable promise in tissue engineering, the mechanical response of these engineered microtissues is not well understood. Here we examine the mechanical and viscoelastic response of progenitor cell aggregates formed from human primary periosteal cells and the resulting cartilaginous microtissues under large deformations as might be encountered in vivo.
View Article and Find Full Text PDFArticle Synopsis
- Clinical guidelines for medications treating gambling disorder are unclear, prompting a network meta-analysis to compare their efficacy and tolerability.
- The study reviewed 22 randomized controlled trials, ultimately analyzing 16 with nearly 1,000 participants, focusing on gambling symptom severity and quality of life as efficacy outcomes.
- Nalmefene showed the most promise in reducing gambling severity and improving quality of life, although it and naltrexone had higher dropout rates due to side effects, indicating lower tolerability compared to placebo.
Purpose: To investigate the pharmacokinetics (PK) of ceftazidime-avibactam (CAZ-AVI) in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF), and compare with a general phase III trial population.
Methods: A prospective PK study was conducted in critically ill patients who received CVVHDF for acute kidney injury, treated with CAZ-AVI (1000/250 mg or 2000/500 mg q8h). Plasma and CVVHDF-circuit samples were collected to determine CAZ-AVI concentrations.
Background: Placebo and nocebo effects are widely reported across psychiatric conditions, yet have seldom been examined in the context of gambling disorder. Through meta-analysis, we examined placebo effects, their moderating factors, and nocebo effects, from available randomised, controlled pharmacological clinical trials in gambling disorder.
Methods: We searched, up to 19 February 2024, a broad range of databases, for double-blind randomised controlled trials (RCTs) of medications for gambling disorder.
Background: Gambling disorder is a common mental health condition, and a growing cause of concern globally. Despite the availability of well-validated self-report and clinical instruments to measure symptom severity, there has been no study to establish optimal thresholds for determining treatment response based on these measures.
Methods: Data from 553 participants (aged 18-65 years) who had participated in previous pharmacological and psychotherapeutic clinical trials for gambling disorder were aggregated.